Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:PRDM1-SLC22A16

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: PRDM1-SLC22A16
	FusionPDB ID: 68440
	FusionGDB2.0 ID: 68440
		Hgene	Tgene
	Gene symbol	PRDM1	SLC22A16
	Gene ID	639	85413
	Gene name	PR/SET domain 1	solute carrier family 22 member 16
	Synonyms	BLIMP1\|PRDI-BF1	CT2\|FLIPT2\|HEL-S-18\|OAT6\|OCT6\|OKB1\|dJ261K5.1
	Cytomap	6q21	6q21\|6q21-q22.1
	Type of gene	protein-coding	protein-coding
	Description	PR domain zinc finger protein 1B-lymphocyte-induced maturation protein 1BLIMP-1PR domain 1PR domain containing 1, with ZNF domainPRDI-binding factor-1beta-interferon gene positive-regulatory domain I binding factor	solute carrier family 22 member 16WUGSC:RG331P03.1carnitine transporter 2epididymis secretory protein Li 18flipt 2fly-like putative organic ion transporter 2fly-like putative transporter 2organic cation transporter 6organic cation transporter OKB1
	Modification date	20200322	20200313
	UniProtAcc	.	.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000369089, ENST00000369091, ENST00000369096,	ENST00000456137, ENST00000461487, ENST00000330550, ENST00000368919, ENST00000439654,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	3 X 3 X 2=18	4 X 5 X 5=100
	# samples	3	9
	** MAII score	log2(3/18*10)=0.736965594166206 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0	log2(9/100*10)=-0.15200309344505 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: PRDM1 [Title/Abstract] AND SLC22A16 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: PRDM1 [Title/Abstract] AND SLC22A16 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	PRDM1(106554374)-SLC22A16(110778220), # samples:1 PRDM1(106554374)-SLC22A16(110763978), # samples:1
Anticipated loss of major functional domain due to fusion event.	PRDM1-SLC22A16 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. PRDM1-SLC22A16 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. PRDM1-SLC22A16 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. PRDM1-SLC22A16 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. PRDM1-SLC22A16 seems lost the major protein functional domain in Hgene partner, which is a CGC due to the frame-shifted ORF. PRDM1-SLC22A16 seems lost the major protein functional domain in Hgene partner, which is a epigenetic factor due to the frame-shifted ORF. PRDM1-SLC22A16 seems lost the major protein functional domain in Hgene partner, which is a transcription factor due to the frame-shifted ORF. PRDM1-SLC22A16 seems lost the major protein functional domain in Hgene partner, which is a tumor suppressor due to the frame-shifted ORF. PRDM1-SLC22A16 seems lost the major protein functional domain in Tgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	PRDM1	GO:0000122	negative regulation of transcription by RNA polymerase II	1851123
Tgene	SLC22A16	GO:0015695	organic cation transport	12089149\|15963465
Tgene	SLC22A16	GO:0015879	carnitine transport	12089149
Tgene	SLC22A16	GO:0046717	acid secretion	12089149

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr6:106554374/chr6:110778220)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across PRDM1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across SLC22A16 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000369091	PRDM1	chr6	106554374	+	ENST00000456137	SLC22A16	chr6	110778220	-	3155	2014	103	2154	683
ENST00000369096	PRDM1	chr6	106554374	+	ENST00000456137	SLC22A16	chr6	110778220	-	3277	2136	57	2276	739
ENST00000369089	PRDM1	chr6	106554374	+	ENST00000456137	SLC22A16	chr6	110778220	-	2787	1646	146	1786	546
ENST00000369091	PRDM1	chr6	106554374	-	ENST00000368919	SLC22A16	chr6	110763978	-	3283	2014	103	3096	997
ENST00000369091	PRDM1	chr6	106554374	-	ENST00000330550	SLC22A16	chr6	110763978	-	3239	2014	103	3096	997
ENST00000369091	PRDM1	chr6	106554374	-	ENST00000439654	SLC22A16	chr6	110763978	-	2911	2014	103	2910	936
ENST00000369096	PRDM1	chr6	106554374	-	ENST00000368919	SLC22A16	chr6	110763978	-	3405	2136	57	3218	1053
ENST00000369096	PRDM1	chr6	106554374	-	ENST00000330550	SLC22A16	chr6	110763978	-	3361	2136	57	3218	1053
ENST00000369096	PRDM1	chr6	106554374	-	ENST00000439654	SLC22A16	chr6	110763978	-	3033	2136	57	3032	991
ENST00000369089	PRDM1	chr6	106554374	-	ENST00000368919	SLC22A16	chr6	110763978	-	2915	1646	146	2728	860
ENST00000369089	PRDM1	chr6	106554374	-	ENST00000330550	SLC22A16	chr6	110763978	-	2871	1646	146	2728	860
ENST00000369089	PRDM1	chr6	106554374	-	ENST00000439654	SLC22A16	chr6	110763978	-	2543	1646	146	2542	799

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000369091	ENST00000456137	PRDM1	chr6	106554374	+	SLC22A16	chr6	110778220	-	0.005145998	0.99485403
ENST00000369096	ENST00000456137	PRDM1	chr6	106554374	+	SLC22A16	chr6	110778220	-	0.005951405	0.9940486
ENST00000369089	ENST00000456137	PRDM1	chr6	106554374	+	SLC22A16	chr6	110778220	-	0.013638919	0.986361
ENST00000369091	ENST00000368919	PRDM1	chr6	106554374	-	SLC22A16	chr6	110763978	-	0.000485123	0.99951494
ENST00000369091	ENST00000330550	PRDM1	chr6	106554374	-	SLC22A16	chr6	110763978	-	0.000554188	0.99944586
ENST00000369091	ENST00000439654	PRDM1	chr6	106554374	-	SLC22A16	chr6	110763978	-	0.001653677	0.9983463
ENST00000369096	ENST00000368919	PRDM1	chr6	106554374	-	SLC22A16	chr6	110763978	-	0.000767333	0.99923265
ENST00000369096	ENST00000330550	PRDM1	chr6	106554374	-	SLC22A16	chr6	110763978	-	0.000823309	0.9991767
ENST00000369096	ENST00000439654	PRDM1	chr6	106554374	-	SLC22A16	chr6	110763978	-	0.001465116	0.9985349
ENST00000369089	ENST00000368919	PRDM1	chr6	106554374	-	SLC22A16	chr6	110763978	-	0.000422112	0.99957794
ENST00000369089	ENST00000330550	PRDM1	chr6	106554374	-	SLC22A16	chr6	110763978	-	0.000532693	0.9994673
ENST00000369089	ENST00000439654	PRDM1	chr6	106554374	-	SLC22A16	chr6	110763978	-	0.002247641	0.99775237

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for PRDM1-SLC22A16

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
PRDM1	chr6	106554374	SLC22A16	chr6	110763978	1646	499	HYLVHTGEKPHECQVASGYLVVGFVY
PRDM1	chr6	106554374	SLC22A16	chr6	110763978	2014	636	HYLVHTGEKPHECQVASGYLVVGFVY
PRDM1	chr6	106554374	SLC22A16	chr6	110763978	2136	692	HYLVHTGEKPHECQVASGYLVVGFVY
PRDM1	chr6	106554374	SLC22A16	chr6	110778220	1646	499	HYLVHTGEKPHECQIPESPLFHMCLP
PRDM1	chr6	106554374	SLC22A16	chr6	110778220	2014	636	HYLVHTGEKPHECQIPESPLFHMCLP
PRDM1	chr6	106554374	SLC22A16	chr6	110778220	2136	692	HYLVHTGEKPHECQIPESPLFHMCLP

Top

Potential FusionNeoAntigen Information of PRDM1-SLC22A16 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

PRDM1-SLC22A16_106554374_110763978.msa
PRDM1-SLC22A16_106554374_110778220.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B45:01	GEKPHECQV	0.9955	0.9018	6	15
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B50:02	GEKPHECQV	0.9848	0.7803	6	15
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B18:01	HECQVASGY	0.9801	0.867	10	19
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B44:03	HECQVASGY	0.9746	0.9103	10	19
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B47:01	HECQVASGY	0.8288	0.6211	10	19
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B41:01	GEKPHECQV	0.3576	0.9038	6	15
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B50:01	GEKPHECQV	0.2949	0.9246	6	15
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B39:13	GEKPHECQV	0.0549	0.9584	6	15
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B45:01	GEKPHECQVA	0.9769	0.9597	6	16
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B50:02	GEKPHECQVA	0.9545	0.8917	6	16
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B50:01	GEKPHECQVA	0.7865	0.9733	6	16
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B41:01	GEKPHECQVA	0.7779	0.9038	6	16
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B35:05	KPHECQVASGY	0.8459	0.5661	8	19
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B40:06	GEKPHECQV	0.9989	0.9127	6	15
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B40:06	GEKPHECQVA	0.9823	0.9581	6	16
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B40:04	GEKPHECQV	0.9943	0.858	6	15
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B18:04	HECQVASGY	0.9859	0.8774	10	19
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B18:08	HECQVASGY	0.9845	0.8844	10	19
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B18:07	HECQVASGY	0.9839	0.8298	10	19
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B18:05	HECQVASGY	0.9801	0.867	10	19
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B44:26	HECQVASGY	0.9746	0.9103	10	19
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B18:06	HECQVASGY	0.9746	0.8761	10	19
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B44:07	HECQVASGY	0.9746	0.9103	10	19
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B44:13	HECQVASGY	0.9746	0.9103	10	19
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B18:03	HECQVASGY	0.969	0.8621	10	19
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B18:11	HECQVASGY	0.9289	0.8514	10	19
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B35:20	HECQVASGY	0.5705	0.8478	10	19
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B35:28	HECQVASGY	0.5651	0.8465	10	19
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B41:03	GEKPHECQV	0.4686	0.6984	6	15
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B50:04	GEKPHECQV	0.2949	0.9246	6	15
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B50:05	GEKPHECQV	0.2949	0.9246	6	15
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B15:53	HECQVASGY	0.1776	0.886	10	19
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B48:02	HECQVASGY	0.1357	0.8259	10	19
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B15:54	HECQVASGY	0.0145	0.8463	10	19
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B50:05	GEKPHECQVA	0.7865	0.9733	6	16
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B50:04	GEKPHECQVA	0.7865	0.9733	6	16
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B35:11	KPHECQVASGY	0.9294	0.8794	8	19
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B15:11	KPHECQVASGY	0.9102	0.8326	8	19
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B35:17	KPHECQVASGY	0.8943	0.7238	8	19
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	1646	HLA-B35:30	KPHECQVASGY	0.8943	0.7238	8	19
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:01	CQIPESPLF	0.9992	0.949	12	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B45:01	HECQIPESP	0.9843	0.9335	10	19
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B50:02	HECQIPESP	0.9748	0.7777	10	19
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:25	CQIPESPLF	0.9625	0.9758	12	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B50:02	GEKPHECQI	0.9375	0.6021	6	15
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:03	CQIPESPLF	0.8465	0.9378	12	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B13:01	CQIPESPLF	0.8123	0.9672	12	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B47:01	CQIPESPLF	0.8002	0.6402	12	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:18	CQIPESPLF	0.7703	0.9011	12	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B41:01	HECQIPESP	0.5543	0.974	10	19
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B50:01	HECQIPESP	0.5185	0.9098	10	19
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-A32:13	CQIPESPLF	0.5072	0.9498	12	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B41:01	GEKPHECQI	0.3173	0.881	6	15
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B50:01	GEKPHECQI	0.1218	0.6403	6	15
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B52:01	CQIPESPLF	0.0911	0.9728	12	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B39:13	GEKPHECQI	0.0558	0.8737	6	15
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B13:01	ECQIPESPLF	0.4805	0.8914	11	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:01	HECQIPESPLF	0.9977	0.9576	10	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B44:03	HECQIPESPLF	0.9969	0.9715	10	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B13:01	HECQIPESPLF	0.9968	0.9556	10	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B18:01	HECQIPESPLF	0.984	0.962	10	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B47:01	HECQIPESPLF	0.9804	0.7395	10	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:03	HECQIPESPLF	0.9725	0.9217	10	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B40:06	GEKPHECQI	0.9969	0.5968	6	15
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B40:06	HECQIPESP	0.9863	0.8852	10	19
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:07	CQIPESPLF	0.9798	0.8005	12	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:04	CQIPESPLF	0.9736	0.9631	12	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:21	CQIPESPLF	0.9452	0.9665	12	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:05	CQIPESPLF	0.9401	0.9643	12	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:31	CQIPESPLF	0.9323	0.9687	12	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:31	ECQIPESPLF	0.7498	0.8351	11	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B40:03	HECQIPESPLF	0.9993	0.6014	10	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:05	HECQIPESPLF	0.9879	0.9539	10	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B44:10	HECQIPESPLF	0.9785	0.6595	10	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:33	CQIPESPLF	0.9992	0.949	12	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:27	CQIPESPLF	0.9992	0.956	12	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:34	CQIPESPLF	0.9992	0.949	12	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:125	CQIPESPLF	0.9992	0.949	12	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:135	CQIPESPLF	0.9991	0.9475	12	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:50	CQIPESPLF	0.9987	0.9136	12	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:24	CQIPESPLF	0.9982	0.9637	12	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B40:04	GEKPHECQI	0.9924	0.6493	6	15
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:53	CQIPESPLF	0.9848	0.9401	12	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:12	CQIPESPLF	0.9668	0.9357	12	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:39	CQIPESPLF	0.9618	0.9549	12	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:35	CQIPESPLF	0.9496	0.9433	12	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:73	CQIPESPLF	0.9495	0.9812	12	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:20	CQIPESPLF	0.9406	0.978	12	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B35:28	CQIPESPLF	0.9309	0.9789	12	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B35:20	CQIPESPLF	0.92	0.9805	12	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:54	CQIPESPLF	0.89	0.9307	12	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:13	CQIPESPLF	0.8804	0.8091	12	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:30	CQIPESPLF	0.8409	0.97	12	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B18:04	CQIPESPLF	0.7815	0.9093	12	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B48:02	CQIPESPLF	0.7791	0.975	12	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B40:21	CQIPESPLF	0.7695	0.5524	12	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:68	CQIPESPLF	0.7599	0.7516	12	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B50:05	HECQIPESP	0.5185	0.9098	10	19
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B50:04	HECQIPESP	0.5185	0.9098	10	19
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B50:04	GEKPHECQI	0.1218	0.6403	6	15
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B50:05	GEKPHECQI	0.1218	0.6403	6	15
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B40:04	HECQIPESPL	0.9834	0.8726	10	20
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:53	ECQIPESPLF	0.8545	0.8599	11	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:24	ECQIPESPLF	0.8282	0.8743	11	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B35:20	ECQIPESPLF	0.7181	0.8726	11	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:12	ECQIPESPLF	0.7131	0.9399	11	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:13	ECQIPESPLF	0.5949	0.7618	11	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:24	HECQIPESPLF	0.9978	0.9714	10	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:27	HECQIPESPLF	0.9978	0.9603	10	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:125	HECQIPESPLF	0.9977	0.9576	10	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:34	HECQIPESPLF	0.9977	0.9576	10	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:33	HECQIPESPLF	0.9977	0.9576	10	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:135	HECQIPESPLF	0.9976	0.9592	10	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:12	HECQIPESPLF	0.9971	0.9444	10	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B44:26	HECQIPESPLF	0.9969	0.9715	10	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B44:13	HECQIPESPLF	0.9969	0.9715	10	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B44:07	HECQIPESPLF	0.9969	0.9715	10	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B40:04	HECQIPESPLF	0.9967	0.875	10	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:53	HECQIPESPLF	0.9957	0.9515	10	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:50	HECQIPESPLF	0.9953	0.9562	10	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:20	HECQIPESPLF	0.9881	0.9723	10	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:54	HECQIPESPLF	0.9876	0.944	10	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B18:11	HECQIPESPLF	0.9844	0.9348	10	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B35:28	HECQIPESPLF	0.9843	0.9736	10	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B18:05	HECQIPESPLF	0.984	0.962	10	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B15:13	HECQIPESPLF	0.979	0.8592	10	21
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	1646	HLA-B48:02	HECQIPESPLF	0.9609	0.9681	10	21

Top

Potential FusionNeoAntigen Information of PRDM1-SLC22A16 in HLA II

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene

Hchr

Hbp

Tgene

Tchr

Tbp

HLA II

FusionNeoAntigen peptide

Neoantigen start (at BP 13)

Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of PRDM1-SLC22A16

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
2751	GEKPHECQIPESPL	PRDM1	SLC22A16	chr6	106554374	chr6	110778220	1646

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
2752	GEKPHECQVASGYL	PRDM1	SLC22A16	chr6	106554374	chr6	110763978	1646

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of PRDM1-SLC22A16

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	2751	GEKPHECQIPESPL	-7.28656	-7.39996
HLA-B14:02	3BVN	2751	GEKPHECQIPESPL	-5.68504	-6.72034
HLA-B52:01	3W39	2751	GEKPHECQIPESPL	-7.45611	-7.56951
HLA-B52:01	3W39	2751	GEKPHECQIPESPL	-4.23128	-5.26658
HLA-A24:02	5HGA	2751	GEKPHECQIPESPL	-5.90012	-6.01352
HLA-A24:02	5HGA	2751	GEKPHECQIPESPL	-5.24438	-6.27968
HLA-B44:05	3DX8	2751	GEKPHECQIPESPL	-6.74318	-6.85658
HLA-B44:05	3DX8	2751	GEKPHECQIPESPL	-3.24185	-4.27715
HLA-A02:01	6TDR	2751	GEKPHECQIPESPL	-7.43467	-7.54807
HLA-B14:02	3BVN	2752	GEKPHECQVASGYL	-7.51877	-7.63217
HLA-B14:02	3BVN	2752	GEKPHECQVASGYL	-6.38909	-7.42439
HLA-B52:01	3W39	2752	GEKPHECQVASGYL	-7.0634	-7.1768
HLA-B52:01	3W39	2752	GEKPHECQVASGYL	-4.74892	-5.78422
HLA-A11:01	4UQ2	2752	GEKPHECQVASGYL	-8.33766	-8.45106
HLA-A24:02	5HGA	2752	GEKPHECQVASGYL	-6.72223	-6.83563
HLA-A24:02	5HGA	2752	GEKPHECQVASGYL	-6.06312	-7.09842
HLA-B44:05	3DX8	2752	GEKPHECQVASGYL	-8.7132	-8.8266
HLA-B44:05	3DX8	2752	GEKPHECQVASGYL	-3.64437	-4.67967

Top

Vaccine Design for the FusionNeoAntigens of PRDM1-SLC22A16

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	10	19	HECQVASGY	GAATGCCAGGTTGCAAGTGGCTATCTT
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	6	15	GEKPHECQV	GAAAAGCCACATGAATGCCAGGTTGCA
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	6	16	GEKPHECQVA	GAAAAGCCACATGAATGCCAGGTTGCAAGT
PRDM1-SLC22A16	chr6	106554374	chr6	110763978	8	19	KPHECQVASGY	CCACATGAATGCCAGGTTGCAAGTGGCTATCTT
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	10	19	HECQIPESP	GAATGCCAGATTCCAGAGAGTCCTCTA
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	10	20	HECQIPESPL	GAATGCCAGATTCCAGAGAGTCCTCTATTT
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	10	21	HECQIPESPLF	GAATGCCAGATTCCAGAGAGTCCTCTATTTCAT
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	11	21	ECQIPESPLF	TGCCAGATTCCAGAGAGTCCTCTATTTCAT
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	12	21	CQIPESPLF	CAGATTCCAGAGAGTCCTCTATTTCAT
PRDM1-SLC22A16	chr6	106554374	chr6	110778220	6	15	GEKPHECQI	GAAAAGCCACATGAATGCCAGATTCCA

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene

Hchr

Hbp

Tchr

Tbp

Start in +/-13AA

End in +/-13AA

FusionNeoAntigen peptide

FusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of PRDM1-SLC22A16

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
BRCA	PRDM1-SLC22A16	chr6	106554374	ENST00000369089	chr6	110763978	ENST00000330550	TCGA-A2-A04V-01A
BRCA	PRDM1-SLC22A16	chr6	106554374	ENST00000369089	chr6	110778220	ENST00000456137	TCGA-A2-A04V-01A

Top

Potential target of CAR-T therapy development for PRDM1-SLC22A16

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Tgene

SLC22A16

chr6:106554374

chr6:110763978

ENST00000330550

183_203

544.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110763978

ENST00000330550

214_234

544.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110763978

ENST00000330550

244_264

544.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110763978

ENST00000330550

268_288

544.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110763978

ENST00000330550

359_379

544.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110763978

ENST00000330550

389_409

544.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110763978

ENST00000330550

416_436

544.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110763978

ENST00000330550

441_461

544.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110763978

ENST00000330550

476_496

544.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110763978

ENST00000330550

501_521

544.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110763978

ENST00000368919

214_234

578.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110763978

ENST00000368919

244_264

578.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110763978

ENST00000368919

268_288

578.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110763978

ENST00000368919

359_379

578.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110763978

ENST00000368919

389_409

578.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110763978

ENST00000368919

416_436

578.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110763978

ENST00000368919

441_461

578.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110763978

ENST00000368919

476_496

578.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110763978

ENST00000368919

501_521

578.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110763978

ENST00000439654

214_234

516.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110763978

ENST00000439654

244_264

516.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110763978

ENST00000439654

268_288

516.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110763978

ENST00000439654

359_379

516.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110763978

ENST00000439654

389_409

516.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110763978

ENST00000439654

416_436

516.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110763978

ENST00000439654

441_461

516.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110763978

ENST00000439654

476_496

516.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110763978

ENST00000439654

501_521

516.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110778220

ENST00000330550

152_172

544.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110778220

ENST00000330550

183_203

544.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110778220

ENST00000330550

214_234

544.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110778220

ENST00000330550

23_43

544.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110778220

ENST00000330550

244_264

544.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110778220

ENST00000330550

268_288

544.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110778220

ENST00000330550

359_379

544.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110778220

ENST00000330550

389_409

544.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110778220

ENST00000330550

416_436

544.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110778220

ENST00000330550

441_461

544.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110778220

ENST00000330550

476_496

544.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110778220

ENST00000330550

501_521

544.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110778220

ENST00000368919

152_172

578.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110778220

ENST00000368919

183_203

578.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110778220

ENST00000368919

214_234

578.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110778220

ENST00000368919

23_43

578.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110778220

ENST00000368919

244_264

578.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110778220

ENST00000368919

268_288

578.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110778220

ENST00000368919

359_379

578.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110778220

ENST00000368919

389_409

578.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110778220

ENST00000368919

416_436

578.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110778220

ENST00000368919

441_461

578.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110778220

ENST00000368919

476_496

578.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110778220

ENST00000368919

501_521

578.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110778220

ENST00000439654

152_172

516.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110778220

ENST00000439654

183_203

516.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110778220

ENST00000439654

214_234

516.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110778220

ENST00000439654

23_43

516.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110778220

ENST00000439654

244_264

516.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110778220

ENST00000439654

268_288

516.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110778220

ENST00000439654

359_379

516.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110778220

ENST00000439654

389_409

516.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110778220

ENST00000439654

416_436

516.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110778220

ENST00000439654

441_461

516.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110778220

ENST00000439654

476_496

516.0

Transmembrane

Helical

Tgene

SLC22A16

chr6:106554374

chr6:110778220

ENST00000439654

501_521

516.0

Transmembrane

Helical

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to PRDM1-SLC22A16

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to PRDM1-SLC22A16

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)